Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02040480
Registration number
NCT02040480
Ethics application status
Date submitted
16/01/2014
Date registered
20/01/2014
Date last updated
13/11/2017
Titles & IDs
Public title
Bioavailability and Food Effect Study of Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib
Query!
Scientific title
A Single Center, Randomized, Open-Label, Sequential, Single Dose, 3-Period Crossover Study to Evaluate the Bioavailability and Food Effect of a Gelatin Formulation and Immediate Release Tablet Formulation of Afuresertib, an AKT Inhibitor, in Normal Healthy Volunteers
Query!
Secondary ID [1]
0
0
201039
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cancer
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - GSK2110183 Gelatin Capsule
Treatment: Drugs - GSK2110183 IR Tablet
Experimental: Sequence 1 - Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ABC
Experimental: Sequence 2 - Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): ACB
Experimental: Sequence 3 - Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BAC
Experimental: Sequence 4 - Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): BCA
Experimental: Sequence 5 - Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CAB
Experimental: Sequence 6 - Participants will receive treatment in following sequence in each of the three study periods (one treatment per period): CBA
Treatment: Drugs: GSK2110183 Gelatin Capsule
White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration
Treatment: Drugs: GSK2110183 IR Tablet
White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Composite of pharmacokinetic (PK) parameters to determine relative bioavailability of afuresertib after administering it as a single dose in an original gelatin capsule in the fasted state and in a newly formulated IR tablet in the fed and fasted state.
Query!
Assessment method [1]
0
0
PK parameters include: area under the plasma concentration-time curve from time zero to infinity (AUC [0-infinity]), area under the plasma concentration time curve from time zero to last time of quantifiable concentration (AUC [0-t]), maximum observed plasma concentration (Cmax), and time to Cmax (tmax).
Query!
Timepoint [1]
0
0
PK Samples will be collected Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120, and 168 hours post-dose
Query!
Secondary outcome [1]
0
0
Number of subjects with adverse events (AEs).
Query!
Assessment method [1]
0
0
AEs will be collected from the start of Study Treatment and until the Follow-up contact.
Query!
Timepoint [1]
0
0
Up to 9 weeks
Query!
Secondary outcome [2]
0
0
Clinical laboratory parameter assessment as a measure of safety and tolerability
Query!
Assessment method [2]
0
0
Laboratory parameters include: hematology, clinical chemistry and urinalysis.
Query!
Timepoint [2]
0
0
Up to 9 weeks
Query!
Secondary outcome [3]
0
0
Concomitant medications review as a measure of safety and tolerability
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Up to 9 weeks
Query!
Secondary outcome [4]
0
0
Electrocardiogram (ECGs) measurement as a measure of safety and tolerability
Query!
Assessment method [4]
0
0
Triplicate 12-lead ECGs will be collected at Screening; in each Dosing Period on Day 1 and Day 3 of Dosing Period; and at Follow-up.
Query!
Timepoint [4]
0
0
Up to 9 weeks
Query!
Secondary outcome [5]
0
0
Vital sign measurement as a measure of safety and tolerability
Query!
Assessment method [5]
0
0
Vital sign measurements will include systolic and diastolic blood pressure and pulse rate.
Query!
Timepoint [5]
0
0
Up to 9 weeks
Query!
Secondary outcome [6]
0
0
Composite of PK parameter following single dose administration of IR tablet in fasted state
Query!
Assessment method [6]
0
0
PK parameters include: AUC (0 - infinity), AUC (0 - t), Cmax, and tmax.
Query!
Timepoint [6]
0
0
PK Samples will be collected Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, 72, 120, and 168 hours post-dose
Query!
Eligibility
Key inclusion criteria
- Provided signed written informed consent
- Healthy Male or female between 18 and 40 years of age inclusive, at the time the
informed consent is obtained.
- Body weight >=50 kilograms (kg) and body mass index (BMI) of >=18 and <= 32 kg/meter
square (m^2).
- A female subject is eligible to participate if she is of (A) Non-childbearing
potential defined as pre-menopausal females with a documented tubal ligation or
hysterectomy or postmenopausal defined as 12 months of spontaneous amenorrhea (B)
Child-bearing potential with negative pregnancy test as determined by serum human
chorionic gonadotropin (hCG) test at Screening and prior to dosing, AND: agrees to use
one of the acceptable contraception methods
- Male subjects with female partners of child-bearing potential must agree to use one of
the contraception methods.
- Alanine aminotransferase, alkaline phosphatase and bilirubin <=1.5xupper limit of
normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated
and direct bilirubin <35%).
- Based on single or averaged QT interval corrected (QTc) values of triplicate ECGs
obtained over a brief recording period: QTcB <450 millisecond (msec); or QTcB <480
msec in subjects with Bundle Branch Block.
- Able to swallow and retain orally administered study treatment and does not have any
clinically significant gastrointestinal (GI) abnormalities that may alter absorption
such as malabsorption syndrome or major resection of the stomach and/or bowels.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
40
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities
(with the exception of Gilbert's syndrome or asymptomatic gallstones).
- History of gastroesophageal reflux disease, dyspepsia, peptic ulcer disease,
gastrointestinal (GI) bleeding, GI surgery that could affect motility.
- History of atrial arrhythmias
- History of regular alcohol consumption within 6 months of the study defined as:
An average weekly intake of >21 units for males or >14 units for females. One unit is
equivalent to 10 grams (g) of alcohol: 270 mL of full strength beer (4.8%), 375 mL of mid
strength beer (3.5%), 470 mL of light beer (2.7%), 250 mL pre-mix full strength spirit
(5%), 100mL of wine (13.5%) and 30 mL of spirit (40%).
- History of sensitivity to any of the study medications, or components thereof or a
history of drug or other allergy that, in the opinion of the Investigator or GSK
Medical Monitor, contraindicates their participation
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody
result within 3 months of Screening.
- Smoking or history or regular use of tobacco- or nicotine-containing products within 6
months prior to screening.
- A positive drug/alcohol screen at Screening or upon check-in to the clinic on Day -1
of each Dosing Period.
- A positive test for human immuno virus (HIV) antibody.
- Pregnant females as determined by positive serum hCG test at Screening or prior to
dosing.
- Where participation in the study would result in donation of blood or blood products
in excess of 500 mL within a 56 day period.
- Lactating females.
- The subject has participated in a clinical trial and has received an investigational
product within the following time period prior to the first dosing day in the current
study: 30 days, 5 half-lives or twice the duration of the biological effect of the
investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first
dosing day.
- Any serious and/or unstable pre-existing medical, psychiatric disorder or other
conditions that could interfere with subject's safety, obtaining informed consent or
compliance to the study procedures.
- Any prohibited medications or recent consumption of citrus products.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/02/2014
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
4/04/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
18
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - Randwick
Query!
Recruitment postcode(s) [1]
0
0
2031 - Randwick
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study is being conducted to measure the relative bioavailability of the original gelatin
capsule formulation and a new formulation, immediate release (IR) tablet of Afuresertib
(GSK2110183). The study will be composed of Screening, Treatment, and Follow-up Periods. A
subject's total time involved in the study will be approximately 9 weeks. The study will
enroll approximately 18 healthy volunteers.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02040480
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02040480
Download to PDF